Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats

Xenobiotica

Volumn 42, Issue 2, 2012, Pages 206-219

  Bertera, Facundo ^a   Di Verniero, Carla Andrea ^a   Mayer, Marcos Alejandro ^a   Chiappetta, Diego ^b   Buontempo, Fabin ^a   Polizio, Ariel Héctor ^a   Taira, Carlos Alberto ^a   Höcht, Christian ^a  

^a Hospital de Pediatria SAMIC Prof Dr Juan P Garrahan   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Carvedilol; Enantioselective pharmacokinetics; Fructose; Hypertension; Metabolic syndrome; PKPD modeling; Sympathetic vascular activity

Indexed keywords

CARVEDILOL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; HEART RATE; HYPERTENSION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARBAZOLES; FRUCTOSE; HEART RATE; HYPERTENSION; MALE; PROPANOLAMINES; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; RATTUS;

EID: 84855424360     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.604746     Document Type: Article

References (46)

1. Aimone LD. (2005). Overview of pharmacokinetics. Curr Protoc Pharmacol 7.1:1-26.
2. Alberti KG, Zimmet P, Shaw J. (2006). Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 23:469-480.
3. Bartsch W, Sponer G, Strein K, Muller-Beckmann B, Kling L, Bohm E, Martin U, Borbe HO. (1990). Pharmacological characteristics of the stereoisomers of carvedilol. Eur J Clin Pharmacol 38 Suppl 2:S104-S107. (Pubitemid 20183992)
4. Bertera FM, Di Verniero CA, Mayer MA, Bramuglia GF, Taira CA, Hocht C. (2009). Is urethane-chloralose anaesthesia appropriate for pharmacokinetic- pharmacodynamic assessment? Studies with carvedilol. J Pharmacol Toxicol Methods 59:13-20.
5. Bertera FM, Mayer MA, Opezzo JA, Taira CA, Hocht C. (2009). Increased sensitivity to diltiazem hypotensive effect in an experimental model of high-renin hypertension. J Pharm Pharmacol 61:79-87.
6. Carella AM, Antonucci G, Conte M, Di Pumpo M, Giancola A, Antonucci E. (2010). Antihypertensive treatment with betablockers in the metabolic syndrome: a review. Curr Diabetes Rev 6:215-221.
7. Catena C, Giacchetti G, Novello M, Colussi G, Cavarape A, Sechi LA. (2003). Cellular mechanisms of insulin resistance in rats with fructose-induced hypertension. Am J Hypertens 16:973-978. (Pubitemid 37315498)
8. D'Argenio DZ, Schumitzky A. (1997). ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource.
9. Di Verniero CA, Bertera F, Buontempo F, Bernabeu E, Chiappetta D, Mayer MA, Bramuglia GF, Taira CA, Hocht C. (2010). Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension. J Pharm Pharmacol 62:890-900.
10. Di Verniero CA, Silberman EA, Mayer MA, Opezzo JA, Taira CA, Hocht C. (2008). In vitro and in vivo pharmacodynamic properties of metoprolol in fructose-fed hypertensive rats. J Cardiovasc Pharmacol 51:532-541.
11. Fazan R Jr, Huber DA, Silva CA, Dias da Silva VJ, Salgado MC, Salgado HC. (2008). Sildenafil acts on the central nervous system increasing sympathetic activity. J Appl Physiol 104:1683-1689.
12. Frishman WH. (1998). Carvedilol. N Engl J Med 339:1759-1765.
13. Fujimaki M. (1992). Stereoselective disposition and tissue distribution of carvedilol enantiomers in rats. Chirality 4:148-154.
14. Gibaldi M, Perrier D. (1982). Pharmacokinetics, 2nd edn. New York: Marcel Dekker.
15. Grassi G, Dell'Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G. (2004). Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 22:2363-2369. (Pubitemid 39620287)
16. Grassi G, Seravalle G. (2006). Autonomic imbalance and metabolic syndrome: unravelling interactions, mechanisms and outcomes. J Hypertens 24:47-49. (Pubitemid 41818087)
17. Grassi G. (1998). Role of the sympathetic nervous system in human hypertension. J Hypertens 16:1979-1987. (Pubitemid 29002377)
18. Hocht C, Bertera FM, Taira CA. (2010). Importance of blood pressure variability in the assessment of cardiovascular risk and benefits of antihypertensive therapy. Exp Rev Clin Pharmacol 3:617-621.
19. Hocht C, Mayer MA, Opezzo JAW, Bertera FM, Taira CA. (2008). Pharmacokinetic-pharmacodynamic modeling of antihypertensive drugs: from basic research to clinical practice. Curr Hypertens Rev 4:289-302.
20. Hsieh PS. (2005). Reversal of fructose-induced hypertension and insulin resistance by chronic losartan treatment is independent of AT2 receptor activation in rats. J Hypertens 23:2209-2217.
21. Hwang IS, Huang WC, Wu JN, Shian LR, Reaven GM. (1989). Effect of fructose-induced hypertension on the renin-angiotensinaldosterone system and atrial natriuretic factor. Am J Hypertens 2:424-427.
22. Hwang IS, Ho H, Hoffman BB, Reaven GM. (1987). Fructose-induced insulin resistance and hypertension in rats. Hypertension 10:512-516. (Pubitemid 18011228)
23. Ishida K, Taira S, Morishita H, Kayano Y, Taguchi M, Hashimoto Y. (2008). Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes. Biol Pharm Bull 31:1297-1300. (Pubitemid 351871190)
24. Kamide K, Rakugi H, Higaki J, Okamura A, Nagai M, Moriguchi K, Ohishi M, Satoh N, Tuck ML, Ogihara T. (2002). The reninangiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats. Am J Hypertens 15:66-71. (Pubitemid 34102275)
25. Keating GM, Jarvis B. (2003). Carvedilol: a review of its use in chronic heart failure. Drugs 63:1697-1741. (Pubitemid 36999963)
26. Louis WJ, McNeil JJ, Workman BS, Drummer OH, Conway EL. (1987). A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. J Cardiovasc Pharmacol 10 Suppl 11:S89-S93.
27. Mayer MA, Hocht C, Gironacci M, Opezzo JA, Taira CA, Fernandez BE, Puyo AM. (2008). Hypothalamic angiotensinergic-noradrenergic systems interaction in fructose induced hypertension. Regul Pept 146:38-45.
28. Mayer MA, Hocht C, Opezzo JA, Taira CA, Fernandez BE, Puyo AM. (2007). High fructose diet increases anterior hypothalamic alpha 2-adrenoceptors responsiveness. Neurosci Lett 423:128-132. (Pubitemid 47259595)
29. Neugebauer G, Akpan W, Kaufmann B, Reiff K. (1990). Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur J Clin Pharmacol 38 Suppl 2:S108-S111. (Pubitemid 20183993)
30. Phuong NT, Lee BJ, Choi JK, Kang JS, Kwon KI. (2004). Enantioselective pharmacokinetics of carvedilol in human volunteers. Arch Pharm Res 27:973-977.
31. Pikkujamsa SM, Huikuri HV, Airaksinen KE, Rantala AO, Kauma H, Lilja M, Savolainen MJ, Kesaniemi YA. (1998). Heart rate variability and baroreflex sensitivity in hypertensive subjects with and without metabolic features of insulin resistance syndrome. Am J Hypertens 11:523-531. (Pubitemid 28270712)
32. Pladys P, Lahaie I, Cambonie G, Thibault G, Le NL, Abran D, Nuyt AM. (2004). Role of brain and peripheral angiotensin II in hypertension and altered arterial baroreflex programmed during fetal life in rat. Pediatr Res 55:1042-1049. (Pubitemid 38661798)
33. Ponchon P, Elghozi JL. (1997). Contribution of humoral systems to the short-term variability of blood pressure after severe hemorrhage. Am J Physiol 273:R58-R69.
34. Prakash AK, Kumar A. (2009). Effect of chronic treatment of carvedilol on oxidative stress in an intracerebroventricular streptozotocin induced model of dementia in rats. J Pharm Pharmacol 61:1665-1672.
35. Ruffolo RR Jr, Gellai M, Hieble JP, Willette RN, Nichols AJ. (1990). The pharmacology of carvedilol. Eur J Clin Pharmacol 38 Suppl 2:S82-S88. (Pubitemid 20183988)
36. Souza HC, Martins-Pinge MC, Dias da Silva VJ, Borghi-Silva A, Gastaldi AC, Blanco JH, Tezini GC. (2008). Heart rate and arterial pressure variability in the experimental renovascular hypertension model in rats. Auton Neurosci 139:38-45.
37. Stahl E, Henke D, Mutschler E, Spahn-Langguth H. (1993). Saturable enantioselective first-pass effect for carvedilol after high oral racemate doses in rats. Arch Pharm (Weinheim) 326: 123-125. (Pubitemid 23115987)
38. Stahl E, Mutschler E, Baumgartner U, Spahn-Langguth H. (1993). Carvedilol stereopharmacokinetics in rats: affinities to blood constituents and tissues. Arch Pharm (Weinheim) 326:529-533. (Pubitemid 23287141)
39. Stauss HM. (2007). Identification of blood pressure control mechanisms by power spectral analysis. Clin Exp Pharmacol Physiol 34:362-368.
40. Su DF, Miao CY. (2005). Reduction of blood pressure variability: a new strategy for the treatment of hypertension. Trends Pharmacol Sci 26:388-390.
41. Tentolouris N, Argyrakopoulou G, Katsilambros N. (2008). Perturbed autonomic nervous system function in metabolic syndrome. Neuromolecular Med 10:169-178.
42. Terao N, Shen DD. (1983). Alterations in serum protein binding and pharmacokinetics of l-propranolol in the rat elicited by the presence of an indwelling venous catheter. J Pharmacol Exp Ther 227:369-375. (Pubitemid 14241128)
43. Tran LT, Yuen VG, McNeill JH. (2009). The fructose-fed rat: a review on the mechanisms of fructose-induced insulin resistance and hypertension. Mol Cell Biochem 332:145-159.
44. Verbeeck RK. (2008). Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147-1161.
45. Verma S, Bhanot S, McNeill JH. (1999). Sympathectomy prevents fructose-induced hyperinsulinemia and hypertension. Eur J Pharmacol 373:R1-R4. (Pubitemid 29306736)
46. Zhou HH, Wood AJ. (1995). Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 57:518-524.